Cingulate Inc. (CINGW) — SEC Filings
Cingulate Inc. (CINGW) — 50 SEC filings. Latest: 8-K (Dec 15, 2025). Includes 31 8-K, 4 10-Q, 4 SC 13D/A.
View Cingulate Inc. on SEC EDGAR
Overview
Cingulate Inc. (CINGW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Cingulate Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $16,177,001, up from $10,328,505 in the prior year, primarily driven by increased operating expenses. Research and development expenses surged to $7,772,109 from $5,116,582, and general
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant filing sentiment for Cingulate Inc. is neutral.
Filing Type Overview
Cingulate Inc. (CINGW) has filed 31 8-K, 4 10-Q, 2 S-1/A, 2 S-1, 3 DEFA14A, 2 DEF 14A, 1 10-K, 1 SC 13G/A, 4 SC 13D/A with the SEC between Jul 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of CINGW's 47 recent filings, 2 were flagged as high-risk, 30 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$16,177,001 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $6,118,710 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. David R. Bear
- Mr. Michael J. Miller
- Shane J. Schaffer
- Michael J. Lerner, Esq.
- Steven M. Skolnick, Esq.
- Dr. David M. Bear
- Dr. Robert J. T. Miller
- Peter J. Werth
Industry Context
The pharmaceutical industry, particularly the development of novel therapeutics, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Cingulate Inc. operate in a competitive landscape where success is heavily reliant on achieving regulatory approval and demonstrating clinical efficacy and safety.
Top Tags
8-K (8) · filing (7) · financials (6) · corporate-governance (6) · sec-filing (6) · disclosure (4) · pharmaceuticals (4) · proxy-statement (4) · Pharmaceuticals (3) · material-agreement (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net loss for nine months ended Sept 30, 2025 | $16,177,001 | Increased from $10,328,505 in prior year, indicating worsening financial performance. |
| Cash and cash equivalents as of Sept 30, 2025 | $6,118,710 | Decreased from $12,211,321 at Dec 31, 2024, highlighting rapid cash burn. |
| Accumulated deficit as of Sept 30, 2025 | $126.1 million | Indicates significant historical losses and contributes to going concern doubt. |
| Research and development expenses for nine months ended Sept 30, 2025 | $7,772,109 | Increased from $5,116,582 in prior year, reflecting ongoing drug development costs. |
| General and administrative expenses for nine months ended Sept 30, 2025 | $6,579,735 | Increased from $4,319,902 in prior year, contributing to higher operating loss. |
| Net cash provided by financing activities for nine months ended Sept 30, 2025 | $7,561,207 | Significantly lower than $24,372,928 in prior year, indicating reduced capital raising success. |
| PDUFA target action date for CTx-1301 | May 31, 2026 | Key regulatory milestone for lead product candidate. |
| SEC File Number | 001-40874 | Identifies Cingulate Inc.'s filing history with the SEC. |
| IRS Employer Identification No. | 86-3825535 | Company's tax identification number. |
| Registration No. | 333-288877 | SEC file number for the S-1/A filing |
| Filing Date | 2025-07-25 | Date the S-1/A was filed with the SEC |
| SIC Code | 2834 | Standard Industrial Classification for Pharmaceutical Preparations |
| Business Address | 1901 W. 47th Place | Principal executive offices of Cingulate Inc. |
| Business Phone | (913) 942-2300 | Contact number for Cingulate Inc. |
| Central Index Key (CIK) | 0001862150 | Unique identifier for Cingulate Inc. with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cingulate Inc. (CINGW)?
Cingulate Inc. has 50 recent SEC filings from Jul 2024 to Dec 2025, including 31 8-K, 4 10-Q, 4 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CINGW filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 48 neutral. The dominant sentiment is neutral.
Where can I find Cingulate Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cingulate Inc. (CINGW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cingulate Inc.?
Key financial highlights from Cingulate Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CINGW?
The investment thesis for CINGW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cingulate Inc.?
Key executives identified across Cingulate Inc.'s filings include Dr. David R. Bear, Mr. Michael J. Miller, Shane J. Schaffer, Michael J. Lerner, Esq., Steven M. Skolnick, Esq. and 3 others.
What are the main risk factors for Cingulate Inc. stock?
Of CINGW's 47 assessed filings, 2 were flagged high-risk, 30 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Cingulate Inc.?
Forward guidance and predictions for Cingulate Inc. are extracted from SEC filings as they are enriched.